- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Combinations of 45 medicines fixed, including Sitagliptin- Metformin, Linagliptin -Metformin combinations
Overview
Through a recent notice, The National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed the retail prices of 45 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 100th Authority meeting dated 05.08.2022.
The said formulations include diabetes medications such as Pure & Cure Healthcare and Cadila Pharma's Sitagliptin and Metformin Hydrochloride (Sustained release) Tablets, Torrent Pharma's Sitagliptin and Metformin Hydrochloride (Sustained release) Tablets, Exemed Pharma and Cipla's Sitagliptin and Metformin Hydrochloride (Sustained release) Tablets, Bajaj Healthcare and J.B. Chemicals & Pharmaceuticals's Sitagliptin Phosphate and Metformin Hydrochloride Tablets, MSN Labs and Eris Lifesciences's Linagliptin and Metformin Hydrochloride extended-release Tablet.
For more details, check out the link given below: